Burlington Stores Inc vs Medpace Holdings Inc — how do they compare? Burlington Stores Inc trades at $354.86 (market cap $22.59B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Burlington Stores Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BURL | MEDP | |
|---|---|---|
Market Cap | $22.59B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $372.19 | $620.59 |
52-Week Low | $242.43 | $393.42 |
Enterprise Value | $27.71B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $353.63, down 4.81% in the last session but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical setup with key support at $346 and resistance at $365, while fundamentals reveal impressive profitability with 39.14% ROE and expanding margins. Recent news highlights the company's successful smaller-store strategy and upward revised 2026 outlook.
BURL presents a compelling growth opportunity with 94% analyst buy ratings and a $367 consensus target offering 3.8% upside. However, elevated valuation multiples (P/E 36.92) and competitive retail pressures warrant caution. The company's debt-to-asset ratio rising to 20.99% in 2026 and recent insider selling of $619,200 worth of shares represent notable risk factors for investors.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →